|
MY132006A
(en)
*
|
2000-05-26 |
2007-09-28 |
Schering Corp |
ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
WO2003022283A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Schering Corporation |
Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
|
|
HUP0401777A3
(en)
|
2001-10-15 |
2008-06-30 |
Schering Corp |
3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
|
|
FR2832405B1
(fr)
*
|
2001-11-19 |
2004-12-10 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
US6916811B2
(en)
*
|
2001-11-30 |
2005-07-12 |
Schering Corporation |
Adenosine A2a receptor antagonists
|
|
IL161573A0
(en)
|
2001-11-30 |
2004-09-27 |
Schering Corp |
[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
BR0306919A
(pt)
|
2002-01-28 |
2004-11-09 |
Kyowa Hakko Kogyo Kk |
Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
|
|
US7064204B2
(en)
*
|
2002-05-30 |
2006-06-20 |
King Pharmacueticals Reserch And Development, Inc. |
Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
TWI331036B
(en)
*
|
2002-12-19 |
2010-10-01 |
Schering Corp |
Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
US20070010522A1
(en)
|
2003-04-09 |
2007-01-11 |
Chi Vu |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
|
AU2004233334B2
(en)
*
|
2003-04-23 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
|
|
US8202869B2
(en)
*
|
2003-06-10 |
2012-06-19 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating an anxiety disorder
|
|
WO2004111004A1
(en)
*
|
2003-06-12 |
2004-12-23 |
Novo Nordisk A/S |
Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
|
|
JP4800216B2
(ja)
*
|
2003-10-24 |
2011-10-26 |
エグゼリクシス， インコーポレイテッド |
ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
|
|
ATE353331T1
(de)
|
2003-10-28 |
2007-02-15 |
Schering Corp |
Verfahren zur herstellung substituierter 5-amino- pyrazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidin
|
|
WO2005054245A2
(en)
*
|
2003-12-01 |
2005-06-16 |
Schering Corporation |
Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
|
|
JP2007514758A
(ja)
|
2003-12-19 |
2007-06-07 |
シェーリング コーポレイション |
医薬組成物
|
|
EP1745047B1
(en)
|
2004-04-21 |
2010-03-24 |
Schering Corporation |
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
|
|
EP2258372B8
(en)
|
2005-06-07 |
2012-12-19 |
Kyowa Hakko Kirin Co., Ltd. |
A2A antagonists for use in the treatment of motor disorders
|
|
CA2622741A1
(en)
|
2005-09-19 |
2007-03-29 |
Schering Corporation |
2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
WO2008008398A2
(en)
*
|
2006-07-14 |
2008-01-17 |
Shionogi & Co., Ltd. |
Oxime compounds and the use thereof
|
|
TW200840566A
(en)
*
|
2006-12-22 |
2008-10-16 |
Esteve Labor Dr |
Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
|
|
US7723343B2
(en)
*
|
2007-03-30 |
2010-05-25 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A2A receptor antagonists
|
|
WO2009110955A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
|
|
WO2009111449A1
(en)
|
2008-03-04 |
2009-09-11 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
|
JP2011513493A
(ja)
|
2008-03-10 |
2011-04-28 |
コーネル ユニバーシティー |
血液脳関門透過性の調節方法
|
|
TWI473614B
(zh)
*
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
|
AU2009274876C1
(en)
|
2008-07-23 |
2016-08-18 |
Kyowa Kirin Co., Ltd. |
Therapeutic agent for migraine
|
|
US20100093702A1
(en)
*
|
2008-10-13 |
2010-04-15 |
Barbay J Kent |
METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
EP2379556A1
(en)
|
2008-12-30 |
2011-10-26 |
ArQule, Inc. |
Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
|
MX2011007678A
(es)
|
2009-01-20 |
2011-08-08 |
Schering Corp |
Metodos para aliviar o tratar señales y/o sintomas asociados con enfermedad de parkinson de moderada a severa.
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
JP5765239B2
(ja)
|
2009-03-13 |
2015-08-19 |
アドヴィナス・セラピューティックス・リミテッド |
置換縮合ピリミジン化合物
|
|
CA2756871A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
US8537177B2
(en)
|
2009-06-15 |
2013-09-17 |
Marvell World Trade Ltd. |
System and methods for gamut bounded saturation adaptive color enhancement
|
|
WO2011017299A2
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
|
|
JP5699152B2
(ja)
|
2009-09-25 |
2015-04-08 |
オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． |
リジン特異的デメチラーゼ−１阻害剤およびその使用
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
|
JP5868948B2
(ja)
|
2010-04-19 |
2016-02-24 |
オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． |
リジン特異的脱メチル化酵素１阻害薬およびその使用
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
JP5843869B2
(ja)
*
|
2010-09-24 |
2016-01-13 |
アドヴィナス・セラピューティックス・リミテッド |
アデノシン受容体拮抗薬としての縮合三環化合物
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012127472A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of preladenant and related compounds
|
|
WO2012129381A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Deuterated preladenant
|
|
WO2013024474A1
(en)
*
|
2011-08-18 |
2013-02-21 |
Mapi Phrarma Ltd. |
Polymorphs of preladenant
|
|
AU2012324803B9
(en)
|
2011-10-20 |
2017-08-24 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
SG11201401066PA
(en)
|
2011-10-20 |
2014-10-30 |
Oryzon Genomics Sa |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
WO2014071512A1
(en)
*
|
2012-11-06 |
2014-05-15 |
Universite Laval |
Combination therapy and methods for the treatment of respiratory diseases
|
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
US10472347B2
(en)
|
2014-11-18 |
2019-11-12 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with A2A antagonist properties
|
|
EP3253390B1
(en)
|
2015-02-06 |
2022-04-13 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
EP3307067B1
(en)
|
2015-06-11 |
2022-11-02 |
Merck Sharp & Dohme LLC |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
TWI801372B
(zh)
*
|
2017-03-30 |
2023-05-11 |
比利時商艾特歐斯比利時有限公司 |
作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
|
|
CN115873022A
(zh)
*
|
2017-03-30 |
2023-03-31 |
伊忒欧斯比利时股份公司 |
作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
|
|
EP3723754A4
(en)
|
2017-12-13 |
2021-05-19 |
Merck Sharp & Dohme Corp. |
IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
|
|
EP3735413B1
(en)
|
2018-01-04 |
2022-07-06 |
Impetis Biosciences Ltd. |
Tricyclic compounds, compositions and medicinal applications thereof
|
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
CN108276345A
(zh)
*
|
2018-03-22 |
2018-07-13 |
重庆奥舍生物化工有限公司 |
一种药物中间体嘧啶-5-甲醛的制备方法
|
|
MX2020010618A
(es)
*
|
2018-04-08 |
2020-11-12 |
Beigene Ltd |
Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
CN108864114B
(zh)
|
2018-06-04 |
2020-11-06 |
应世生物科技(南京)有限公司 |
选择性a2a受体拮抗剂
|
|
CN113166153B
(zh)
|
2018-07-05 |
2024-11-01 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
CN110742893B
(zh)
*
|
2018-07-23 |
2024-04-05 |
百济神州(北京)生物科技有限公司 |
A2a受体拮抗剂治疗癌症的方法
|
|
KR102653800B1
(ko)
|
2018-11-30 |
2024-04-01 |
머크 샤프 앤드 돔 엘엘씨 |
아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
|
|
KR20210116488A
(ko)
|
2018-12-20 |
2021-09-27 |
인사이트 코포레이션 |
액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US12325708B2
(en)
|
2019-05-03 |
2025-06-10 |
Nektar Therapeutics |
Adenosine 2 receptor antagonists
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
EP3999513A4
(en)
*
|
2019-07-17 |
2022-12-21 |
Teon Therapeutics, Inc. |
ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
|
|
CN112625050B
(zh)
|
2019-07-30 |
2021-10-01 |
杭州阿诺生物医药科技有限公司 |
一种a2a和/或a2b受体抑制剂的制备方法
|
|
CN112608316B
(zh)
|
2019-07-30 |
2022-10-21 |
厦门宝太生物科技股份有限公司 |
一种吡唑并三嗪类腺苷受体拮抗剂
|
|
CN111072675A
(zh)
*
|
2019-12-12 |
2020-04-28 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
CN113773327B
(zh)
*
|
2021-09-13 |
2022-07-15 |
八叶草健康产业研究院(厦门)有限公司 |
一种吡唑并嘧啶并三唑环类化合物的制备方法
|
|
CN117946123A
(zh)
*
|
2024-01-26 |
2024-04-30 |
北京脑重大疾病研究院 |
放射性三氮唑并嘧啶基衍生物及其制备方法和应用
|
|
CN118812539B
(zh)
*
|
2024-06-19 |
2025-11-28 |
苏州大学 |
一种5-氨基三唑并嘧啶衍生物及其制备方法
|
|
CN118812544A
(zh)
*
|
2024-06-19 |
2024-10-22 |
厦门大学 |
一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
|